A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (NCT03390504)
A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
Who can join: Review the eligibility criteria below.
Location: Alaska Urological Institute dba Alaska Clinical Research Center — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (345 Sites)
Showing the first 25 of 345 sites.
- Alaska Urological Institute dba Alaska Clinical Research Center — Anchorage, Alaska
- University of Calif Davis Medical Center — Sacramento, California
- St. Helena Hospital - Martin-O'Neil Cancer Center — St. Helena, California
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- University of Miami Sylvester Cancer Center — Miami, Florida
- Mid Florida Hematology Oncology — Orange, Florida
- Piedmont Cancer Institute — Atlanta, Georgia
- Rush University — Chicago, Illinois
- Edward Hines Jr V A Hospital — Hines, Illinois
- Norton Cancer Institute — Louisville, Kentucky
- Maryland Oncology Hematology, PA — Lanham, Maryland
- University of Michigan Health System — Ann Arbor, Michigan
- VA Sierra Nevada Health Care System — Reno, Nevada
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- Weill Cornell Medical College — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Levine Cancer Institute, Carolinas HealthCare System — Charlotte, North Carolina
- W G Bill Hefner VA Medical Center — Salisbury, North Carolina
- Oncology Hematology Care — Cincinnati, Ohio
- The Center for Cancer and Blood Disorders — Fort Worth, Texas
- Texas Oncology-Memorial City — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology Tyler — Tyler, Texas
- INOVA Dwiight &Martha Schar Cancer Institute — Fairfax, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urothelial Cancer
- Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Chandler, Arizona
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer — Cleveland, Ohio
- A Genotype-Phenotype Urothelial Cancer Registry — Basking Ridge, New Jersey
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies — Bethesda, Maryland
- Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer — Los Angeles, California
Explore by condition: All Urothelial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.